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Abstract 
Background: Preliminary evidence suggests that the enteric microbiota may play a role in the expression of neu‑
rological symptoms in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Overlapping symptoms with 
the acute presentation of d‑lactic acidosis has prompted the use of antibiotic treatment to target the overgrowth of 
species within the Streptococcus genus found in commensal enteric microbiota as a possible treatment for neurologi‑
cal symptoms in ME/CFS.
Methods: An open‑label, repeated measures design was used to examine treatment efficacy and enable sex com‑
parisons. Participants included 44 adult ME/CFS patients (27 females) from one specialist medical clinic with Strep-
tococcus viable counts above 3.00 × 105 cfu/g (wet weight of faeces) and with a count greater than 5% of the total 
count of aerobic microorganisms. The 4‑week treatment protocol included alternate weeks of Erythromycin (400 mg 
of erythromycin as ethyl succinate salt) twice daily and probiotic (d‑lactate free multistrain probiotic, 5 × 1010 cfu 
twice daily). 2 × 2 repeated measures ANOVAs were used to assess sex‑time interactions and effects across pre‑ and 
post‑intervention for microbial, lactate and clinical outcomes. Ancillary non‑parametric correlations were conducted 
to examine interactions between change in microbiota and clinical outcomes.
Results: Large treatment effects were observed for the intention‑to‑treat sample with a reduction in Streptococcus 
viable count and improvement on several clinical outcomes including total symptoms, some sleep (less awaken‑
ings, greater efficiency and quality) and cognitive symptoms (attention, processing speed, cognitive flexibility, story 
memory and verbal fluency). Mood, fatigue and urine d:l lactate ratio remained similar across time. Ancillary results 
infer that shifts in microbiota were associated with more of the variance in clinical changes for males compared with 
females.
Conclusions: Results support the notion that specific microorganisms interact with some ME/CFS symptoms and 
offer promise for the therapeutic potential of targeting gut dysbiosis in this population. Streptococcus spp. are not the 
primary or sole producers of d‑lactate. Further investigation of lactate concentrations are needed to elucidate any 
role of d‑lactate in this population. Concurrent microbial shifts that may be associated with clinical improvement (i.e., 
increased Bacteroides and Bifidobacterium or decreased Clostridium in males) invite enquiry into alternative strategies 
for individualised treatment.
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Background
Background and objectives
ME/CFS is a complex, neuroimmune condition char-
acterised by post-exertional mental and physical fatigue 
that is disproportionate to the level of exertion [1]. The 
multisystemic dysregulation results in pathophysiologi-
cal abnormalities affecting a combination of central 
nervous, immune, gastrointestinal, energy metabolism, 
cardiovascular and respiratory systems manifesting in 
heterogeneous symptomatic presentations [1]. The his-
tory of diagnostic discrepancies (see [1–4]) is reflected in 
varied prevalence rates between .08 and 2.6% [5–11] but 
the burden on both the patient, their family and society is 
unequivocal [12]. This burden is not only a result of the 
devastating impact that the condition has on the patient’s 
daily, occupational and social functioning [13–15] but 
can also be attributed to the direct cost of medical care 
that is often exacerbated by misdiagnosis and unclear 
treatment pathways [16, 17]. This awareness provides the 
rationale to examine the efficacy of treatments targeting 
pathophysiological abnormalities in ME/CFS patients 
with the hope of minimizing clinical exploration and 
identifying subgroups that may be more responsive to 
specific treatments.
Gastrointestinal disturbance and comorbid irritable 
bowel syndrome (IBS) are common in ME/CFS [18]. Esti-
mates from a clinical sample of 1400 patients found that 
80–90% experienced recurring gastrointestinal symp-
toms [19]. Intestinal permeability of the mucosal lining 
of the gastrointestinal tract [20, 21] and an imbalance in 
commensal enteric bacteria (i.e., gut dysbiosis) using cul-
ture-based methods (i.e., microbiota [22, 23]) and DNA 
sequencing (i.e., microbiome [24–26]) have also been 
shown in this population. These imbalances in both the 
microbiota and microbiome appear distinct from healthy 
controls [24, 26], and associated with inflammation [25] 
and symptom expression [23, 26–29]. Accumulating evi-
dence suggests that microbial imbalances (whether con-
sequential or causative) should not be viewed in isolation 
as they may be relevant for multiple ME/CFS symptoms, 
including but not limited to neurological manifestations.
Gut–brain interaction occurs through multiple bidirec-
tional pathways including through central, autonomic, 
and enteric nervous systems; neuroendocrine and neu-
roimmune pathways; and enteric microbiota [30–32]. 
Our understanding of the importance of the symbiotic 
relationship between enteric microbiota and health is 
becoming well accepted, with research efforts directed 
towards understanding mechanisms of microbial/host 
communication (see [33]). Gut dysbiosis may directly or 
indirectly precede gastrointestinal, neurocognitive and 
immune disturbances [34] or may be a consequence of 
stress and neurobiological mechanisms (e.g., in animal 
models [35–37]). Results of antibiotic [27], probiotic [38–
40] and faecal transplant [41] interventions provide pre-
liminary support for microbiota–gut–brain interactions 
in ME/CFS.
The d-lactate theory has been proposed as a possible 
mechanism for the neurological disturbances associated 
with gut dysbiosis in this population [23, 34, 42]. d-Lactic 
acidosis is an acute metabolic acidosis with associated 
encephalopathy that is observed in patients with a his-
tory of small bowel resections [43]. The shortened small 
bowel can lead to impaired absorption of carbohydrates, 
preferential growth of selected gut bacteria (e.g., increase 
in some species of Lactobacillus and Streptococcus) that 
promotes an acidic colonic environment and excess pro-
duction of d-lactic acid [44]. This abundance of d-lactic 
acid combined with decreased metabolic capacity can 
lead to excess absorption within the blood and brain 
believed to play a role in the neurological symptoms of 
d-lactic acidosis [44]. Within ME/CFS, an overgrowth 
of Streptococcus and Enterococcus species (d-lactic acid 
producing bacteria) has been observed in culture-based 
microbial studies [23]. This bacterial imbalance, com-
bined with overlapping neurological symptoms and pos-
sible mechanisms have contributed to the proposal that 
subclinical concentrations of d-lactate may play a role 
in ME/CFS presentations [42]. To date, measurement 
of d-lactate concentrations in ME/CFS have not been 
published.
In accordance with the d-lactate theory, an antibiotic 
treatment has been proposed to target the overgrowth 
of commensal enteric microbiota within the Streptococ-
cus genus. Results from our group’s earlier pilot showed 
initial promise on some sleep and mood outcomes for a 
subgroup of participants who decreased in Streptococcus 
after 6  days of oral erythromycin treatment [27]. Other 
probiotic interventions used with ME/CFS patients may 
contradict the d-lactate hypothesis. Results indicating 
Trial Registration Australian and New Zealand Clinical Trial Registry (ACTRN12614001077651) 9th October 2014. 
https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=366933&isReview=true
Keywords: Antibiotic, Chronic fatigue syndrome, Clinical outcomes, Gut dysbiosis, Microbiota‑gut‑brain, Myalgic 
encephalomyelitis, Neuropsychological symptoms, Open‑label pilot, Probiotic, Sex comparisons, Streptococcus, 
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improved neurocognitive [38] and anxiety [39] symptoms 
using lactic acid-producing bacteria (predominantly 
Lactobacillus strains) question the mechanisms at play. 
Notably, colonic bacteria can produce d- and l-lactate 
with the ratio and rate of metabolism dependent on the 
species [45]. The proportion of d:l lactate produced by 
the bacterial strains used in the probiotic studies were 
not measured. The validity of the d-lactate theory as well 
as the efficacy of antibiotic and probiotic interventions in 
ME/CFS requires further examination.
Findings from our cross-sectional study correlating 
commensal microbiota and clinical symptoms in 274 
ME/CFS patients [28] provided an interesting perspec-
tive on the role of d-lactate in males and females. Results 
showed small to moderate positive correlations for both 
Streptococcus and Lactobacillus with symptoms in males, 
suggesting that increased abundance of these genera 
were related to more impairment across several ME/
CFS symptoms [28]. For Streptococcus, opposite associa-
tions were shown in females with small negative correla-
tions suggesting that higher Streptococcus was associated 
with less pain, neurosensory and immune symptoms. 
These results highlighted the importance of considering 
sex differences in microbial function and supported the 
notion of the ‘microgenderome’, i.e. the critical role of sex 
hormones on host–microbiota interactions [46]. These 
findings also raised questions about the possibility of sex 
differences in response to oral erythromycin treatment 
targeting an overgrowth of Streptococcus.
This study is positioned within the context of d-lac-
tate and microgenderome theories. In light of research 
yielding sex-specific correlations between Streptococci 
and ME/CFS symptoms [28], the objective of this study 
was to examine whether there was a sex-specific treat-
ment response to an intervention designed to reduce 
the content of bacteria of the Streptococcus genus. Thus 
this pilot study compares the treatment response of male 
and female ME/CFS patients using a combined antibi-
otic and probiotic intervention aimed at reducing Strep-
tococcus. Clinical outcomes measuring sleep, mood and 
cognitive symptoms were prioritised. The intervention 
was an extension of the earlier pilot [27] with alternate 
weeks of oral erythromycin and d-lactate-free probiotic 
supplementation across a 4-week period. Urine d-lac-
tate and l-lactate concentrations were also measured to 
observe variation of lactate levels with this intervention 
to understand possible mechanisms of microbial–gut–
brain interactions. To enable sufficient sample sizes for 
sex comparisons, an open-label design was used with the 
primary feasibility objective of determining the appro-
priateness of the intervention for both sexes rather than 
placebo control.
Methods
Trial design and participant recruitment
This open-label, non-randomised pilot used a repeated 
measures design with a baseline, intervention and post-
intervention protocol across 6  weeks (see Table  1). The 
prospective intention was to recruit 40 patients with 
equal proportions of males and females to enable sex 
comparisons. Screening and recruitment was continu-
ous, with consecutive commencement dates according to 
patient presentation at CFS Discovery Clinic, Melbourne, 
Australia.
New or current patients at the clinic aged above 
18 years who met Canadian Consensus diagnostic Crite-
ria for ME/CFS [47] were invited to be screened for par-
ticipation in this study. Eligible participants were patients 
with Streptococcus viable counts above 3.00 × 105 cfu/gm 
and more than 5% of the total count of aerobic microor-
ganisms. Participants were asked to refrain from taking 
other antibiotics (from 4  weeks prior), probiotics (from 
2 weeks prior), and substantially altering their diet, pre-
scription medications or over-the-counter supplements 
across the screening and trial period. Known adverse 
reactions, contra-indications to the treatment protocol 
and/or significant comorbid physical or psychiatric ill-
nesses excluded participation.
Trial methods were conducted in accordance with the 
guidelines for human experimental research and the 
Australian Clinical Trial Handbook [48]. Ethics approval 
was obtained from Victoria University Human Research 
Ethics Committee in June 2015 (HRE15-010). Additional 
trial details are available on the Australian and New Zea-
land Clinical Trial Registry (ACTRN12614001077651).
Intervention
The treatment protocol combined antibiotic and probi-
otic therapy taken on alternate weeks. Tablets of Eryth-
romycin 400  mg were given twice daily during weeks 2 
and 4 (Erythromycin was given as the Ethyl Succinate 
salt and supplied by Amdipharm Mercury Pty Ltd or by 
Alphapharm Pty Ltd). Two capsules of Pro4-50 d-lac-
tate free multistrain probiotic (Spectrumceuticals Pty 
Ltd, Belrose, New South Wales, Australia) were taken 
daily during weeks 3 and 5. Each probiotic capsule con-
tained Lactobacillus rhamnosus (2.5 ×  1010 cfu), Bifido-
bacterium lactis (1.5 ×  1010  cfu), Bifidobacterium breve 
(5 × 106 cfu), Bifidobacterium longum (5 × 106 cfu). The 
off-label use of Erythromycin required notification to the 
Therapeutic Goods Administration under the Clinical 
Trial Notification scheme (Trial Number: 2015/0492) and 
approval was obtained on 29 June 2015.
Participants completed the intervention in their own 
homes. Compliance and adverse events were monitored 
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with weekly phone calls throughout the intervention 
phase and participant completion of treatment adher-
ence schedules.
Outcomes
Table  1 provides an overview of the timing of the out-
comes assessed. Sleep patterns were measured objec-
tively (actigraphy) using wrist Actiwatch monitors 
(Respironics Actiwear 2) that estimate movement and 
light. Participants completed a Response Booklet that 
included the sleep diary and self-report scales. Partici-
pants attended two external appointments for adminis-
tration of the Cognitive Test Battery. The Cognitive Test 
Battery included measures of attention, memory, verbal 
fluency and executive functioning (see Additional file 1: 
Additional Method for additional details of all clinical 
measures and selected outcome variables).
The faecal microbial counts were performed on speci-
mens that were preserved by cooling and then controlling 
the temperature until the commencement of labora-
tory analysis (see Additional file  1: Additional method). 
Classical cultural methods, on a variety of media, 
were used to perform the counts (see [28] for details of 
microbial identification and microbial quantification 
procedures). Identification of bacteria was performed 
by Matrix Assisted Laser Absorption and Ionisation 
Time of Flight Mass Spectrometry (MALDI-TOF–MS) 
using a proprietary peptide data base (MALDI Biotyper 
Bruker Daltonics, Bremen, Germany). Microbial vari-
ables included the count and relative abundance (RA) of 
selected aerobic (Streptococcus, Enterococcus, Escheri-
chia) and anaerobic bacteria (Bacteroides, Bifidobacte-
rium, Clostridium, Eubacterium, Lactobacillus). These 
variables were selected based on prior research [28]. 
 RAtotal was calculated by the ratio of each genus count 
divided by total detectable bacteria count (aerobic and 
anaerobic). The proportion of Streptococcus within total 
aerobic bacteria count  (RAaerobe) was also used as an out-
come measure to be consistent with inclusion criteria 
and aid clinical interpretation.
The d-lactate and l-lactate concentrations in the urine 
samples were determined using High Performance Liq-
uid Chromatography and Triple Quadrupole Mass 
Spectrometry (HPLC-TMS). Briefly, urine samples were 
acidified with hydrochloric acid and extracted with ethyl 
acetate. The ethyl acetate extracts were evaporated in a 
centrifugal vacuum evaporator. The residues were deriv-
itised with an optically active reagent, (+)-O,O-diacetyl-
l-tartaric anhydride, as originally described by Scheijen 
et  al. [49]. These data are presented as the ratio of the 
concentrations of d-lactate to l-lactate. It is common to 
determine the ratio of analyte concentration in the urine 
sample the concentration of creatinine in the sample in 
order to correct for dilute or concentrated urine samples 
Table 1 Trial design
a Participants had the option of completing these scales at any time during Baseline and Post-intervention phases if they wanted to reduce the risk of post-exertional 
mental fatigue
Week 1 2 3 4 5 6
Day 1–7 8–14 15–21 22–28 29–35 36–42
Phase Screening/
recruitment
Baseline Intervention Post-intervention
Treatment 
prescribed
Antibiotic
Erythromycin
400 mg/b.d.
Probiotic
Pro4‑50 d‑Lactate 
Free Multistrain
1 tablet b.d.
Antibiotic
Erythromycin
400 mg/b.d.
Probiotic
Pro4‑50 d‑Lactate 
Free Multistrain
1 tablet b.d.
Measures/
monitoring
• Consent forms
• Screening and 
background 
questions
• Stool and urine 
collection
Day 1
• Cognitive test 
battery
Days 1–7
• Actigraphy
• Sleep diary
• MAC
• MFTQ
Day 7a
• SSH
• DASS‑21
• MFI‑20
• POMS
• PSQI
• ISI
Day 14
• Phone call, 
symptom 
monitoring
Day 21
• Phone call, 
symptom 
monitoring
Day 28
• Phone call, 
symptom 
monitoring
Day 35
• Phone call, 
symptom 
monitoring
Day 1
• Cognitive test 
battery
Days 1–7
• Actigraphy
• Sleep diary
• MAC
• MFTQ
• Stool and urine 
collection
Day 7a
• SSH
• DASS‑21
• MFI‑20
• POMS
• PSQI
• ISI
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that arise from variation in the state of hydration of the 
subject. This was considered inappropriate in the current 
trial because there is evidence that the excretion of cre-
atinine is increased in subjects suffering from ME/CFS 
(see [50]).
Primary and secondary outcomes
Primary and secondary endpoints were the change in 
scores on psychological outcomes at post-intervention 
for the intention-to-treat (ITT) population (i.e., all par-
ticipants who commenced at baseline). A priori alloca-
tion of primary outcome status was based on evidence 
from research indicating sensitivity measuring treatment 
effects in this [27] and other clinical populations [51]. 
Primary outcome variables included a measure of sleep 
(actigraphic sleep efficiency; SE), mood (Profile of Mood 
States-Short Form Total Mood Disturbance, POMS [52]) 
and a measure of sustained visual attention (Rapid Visual 
Processing-A′, RVP-A′ from the Cambridge Neuropsy-
chological Test Automated Battery, CANTAB [53]).
Multiple secondary endpoints were selected to evalu-
ate change in microbiota (Streptococcus, Bifidobacteria 
and Lactobacillus count and RA), urinary d-lactate (d:l 
lactate ratio) and clinical symptoms including: objective 
sleep symptoms [Actigraphy sleep onset latency (SOL), 
wake after sleep onset (WASO), and restlessness/sleep 
fragmentation index (SFI)]; subjective sleep symptoms 
(Sleep Diary SOL, WASO, SE, and the Pittsburgh Sleep 
Quality Index, PSQI—Global Score [54]); mood (Depres-
sion, Anxiety and Stress Scale, DASS-21 [55]); cognition 
(word memory, story memory, spatial working memory, 
visual learning, verbal fluency, processing speed, cogni-
tive flexibility and planning); fatigue (General Fatigue 
subscale from the Multidimensional Fatigue Inventory, 
MFI-20 [56]); and the Brain Fog subscale of the Multi-
ple Fatigue Types Questionnaire, MTFQ [57]); and total 
symptoms (Symptom Severity and Symptom Hierarchy 
Profile, SSH-Total score [47]).
Uncertainty about the suitability of endpoints sug-
gested a less hierarchical approach to outcome classi-
fication. Subsequently, the results of both primary and 
secondary outcome variables are presented together pri-
oritising outcomes with large effect sizes (ES).
Sample size
The study aimed to recruit equal proportions of males 
and females to conduct sex comparisons. Power analyses 
conducted by G*Power 3.1 indicated that the minimum 
sample size of n = 20 per group (alpha = .05, power = .8) 
would enable moderate to large ES estimates to achieve 
significance using analysis of variance (2  ×  2 repeated 
measures ANOVA). A sample size of 40 for the combined 
group (alpha = .05, power = .8) was required to identify 
significant, moderate ES estimates using repeated meas-
ures ANOVA within factors (f = .23).
Statistical methods
Group comparisons for primary and secondary outcomes
Using SPSS version 22.0 [58], mixed between-within 
subjects analysis of variance (2  ×  2 repeated measures 
ANOVA) assessed the sex-time interaction effect and 
main effects (time and sex) for each outcome. These were 
performed for the whole sample (according to ITT pro-
tocols). Cases with missing data were excluded for pair-
wise analyses to retain maximum representation for each 
variable.
Focus on  effect estimates As encouraged by the CON-
SORT guidelines, it was decided to prioritise estimates of 
ES values and their confidence intervals (CI) [59]. Partial 
eta squared 
(
µ
2
p
)
 values are reported as the ES estimate 
produced by ANOVA analyses in SPSS software. Cohen’s 
[60] guidelines for interpreting partial eta squared were 
employed (small =  .01, moderate =  .06, large =  .14). A 
conservative approach was used to avoid over-interpreta-
tion and the risk of Type 1 errors with multiple outcomes. 
Therefore, only outcomes with large effect sizes were used 
to examine treatment efficacy. Wuensch’s [61] explana-
tions and Smithson’s syntax scripts for use in SPSS soft-
ware were used to obtain 90% ES confidence intervals. 
Wuensch [61] explains that 90% confidence intervals are 
preferred because they are consistent with the ANOVA 
results and the .05 criterion of statistical significance. 
Additionally, partial eta squared values can only be posi-
tive values and a 95% confidence interval can include 
negative values. Exact significance values (P) are provided 
without use of Bonferroni corrections or the dichotomous 
categorisation of significance levels.
Assumptions: tests used and managing violations
Normality
Each outcome variable was assessed for normality using 
the Shapiro–Wilk test in SPSS. Mild violations in normal-
ity were seen across several clinical variables, microbial RA 
and d:l lactate ratio variables. These variables were not 
transformed in accordance with criticisms of using trans-
formations in psychosocial and biomedical research [62].
However, large violations in normality were seen on 
all microbial count variables. The nature of exponen-
tially large values provided the rationale to transform 
these variables. Log10 transformations were applied and 
resulted in improvements in normality. Results were 
back-transformed after analysis and presented in the 
original scale as recommended [63].
Parametric tests were performed with minor viola-
tions of normality after considering that (a) ANOVA is 
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robust to violations of normality for samples larger than 
30 [64] and (b) nonparametric alternatives (Wilcoxon 
Signed Rank and Sign Test) exclude ties and, therefore, 
oppose the theoretical premise of ITT analyses. Means 
and standard deviations at baseline and post are pre-
sented based on cases with pairwise comparisons in each 
2 × 2 ANOVA (see Additional file 1: Table S1). In order 
to address possible concerns about the spread of scores 
and appropriately describe the data, median and range 
scores for ITT data at baseline and post are presented in 
Additional file 1: Table S2.
Homogeneity tests Homogeneity tests were calculated 
during repeated measures ANOVA procedures. The Lev-
ene’s test was used to determine equality of error vari-
ances. Given that p values are provided, violations of this 
assumption (p < .05) are highlighted in Additional file 2: 
Table S3 to attempt to mitigate inaccurate interpretation. 
For readers focusing on probability statistics, it is recom-
mended to use a more stringent interpretation of signifi-
cance values for interaction and main effects when the 
Levene’s test is violated (i.e., p <  .01; [64]). The Box’s M 
test was used to determine if the assumption of homoge-
neity of intercorrelations was met (p ≥ .001; [65]).
Ancillary exploratory analyses: correlations
The results of primary analyses indicated the need for 
further investigation to understand outcomes and exam-
ine interactions between change in bacteria and change 
in symptoms. Correlations were chosen as the preferred 
method due to restrictions with sample size and viola-
tions of assumptions with other statistical techniques 
(i.e., MANOVA or regression). Proportional change 
scores were created for each clinical, microbial count and 
d:l lactate ratio variable using Eq. (1).
where X represents each variable analysed.
Therefore, scores of 100 reflect no change at post and 
numbers above or below reflect an increase or decrease 
at post, respectively. Spearman’s rho correlations (rs) 
between change in clinical variables and change in 
microbial variables were chosen due to violations in 
normality. Missing cases were excluded pairwise. To 
allow for consistent interpretation of correlations, 
some rs values were reversed (multiplied by −  1) so 
that a decrease in the clinical outcome score always 
represented improvement. Correlations were classi-
fied as small (.01), moderate (.03) and large (.05) effect 
sizes [66]. Only large effect sizes (i.e., rs  >  .05) were 
(1)XChange =
PostX
PreX
× 100
interpreted to reduce the risk of Type 1 errors from 
multiple correlations.
Results
Participant recruitment and demographics
Figure  1 shows the participant flow diagram with 44 
patients deemed eligible and consenting to participate 
from the 98 screened during recruitment (44.9%). A 
predominance of females (n =  27) were recruited com-
pared with males (n = 17). The recruitment period was 
between 29th July 2015 and 8th November 2016. The 
date of the last data collection was 26th December 2016. 
All participants completed both baseline and post-inter-
vention stages.
Baseline demographics for all participants are pre-
sented in Table  2. Participants were aged between 18 
and 65 years with mean ages similar between the sexes. 
On average females spent less time working per week 
with 15/23 females (65.2%) not working compared with 
5/14 males (35.7%). Higher mean scores of baseline gen-
eral fatigue were reported by female (MFI-20, General 
Fatigue: M = 18.0, SD = 2.4) compared with male (MFI-
20, General Fatigue: M  =  15.7, SD  =  3.4) participants 
although the range of scores on this subscale indicate 
individual variability across both groups. Mean scores for 
both sexes suggest ‘severe’ fatigue as indicated by scores 
above 13 [67]. (Possible scores on the MFI-20 range from 
4 to 20 [56], and healthy controls average 6.8 on this sub-
scale (see [67]). The mean years since diagnosis of ME/
CFS was approximately 10  years for the total sample, 
female and male participants. The majority of partici-
pants (39/44) adhered to the treatment protocol (self-
reported taking  >  90% of the combined antibiotic and 
probiotic intervention).
Outcomes and estimation
Descriptive results, ES estimates and exact significance 
levels obtained from 2 ×  2 ANOVAs are presented for 
the total ITT sample and stratified by sex (Additional 
file 1: Table S1). Some outcomes had missing data due to 
incomplete responses (questionnaires), collection error 
(stool and urine samples), and/or technical error (actigra-
phy). Management procedures for missing and ambigu-
ous data are presented in the Additional file 1: Additional 
Method. Analysis of the change in scores from baseline 
to post for male and female subgroups (sex-time inter-
actions) revealed no large effects and thus did not sup-
port a sex-specific response to the treatment (µ2p <  .014 
for each outcome variable, see Additional file  1: Table 
S1). However, several dependent variables revealed a 
change across the intervention (i.e., time effects) when 
considering the sample as a whole. Figure  2 shows the 
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Recruitment Assessed for eligibility (n = 98)
Females (n = 27)
Eligible (n = 44)
Analysed intention-to-treat (n = 44)
Allocated to intervention (n = 44) 
• Received allocated intervention  
(n = 44)
Lost to post-intervention (n = 0)
Excluded (n = 54) 
• Not meeting Streptococcus 
inclusion criteria (n = 39) 
• New treatment introduced since 
screening (n = 7) 
• Declined to participate (n = 5) 
• Suspected allergy to probiotic 
(n = 1) 
• Other reasons (n = 2, unrelated 
surgery and unable to 
commence within trial period).
Males (n = 17)
Allocation
Follow-Up
Analysis
Fig. 1 Participant flow diagram
Table 2 Baseline demographics for intention-to-treat sample stratified by sex
Information about the duration of the illness was also described by classifying into two groups of shorter (≤ 3 years) and longer (> 3 years) duration using the same 
ranges as in Hornig et al. [89]
a Data reflects mean (standard deviation) or frequency (%)
b Multidimensional Fatigue Inventory-20 (MFI-20) general fatigue subscale scores range from 4 to 20 [56] with severe fatigue indicated by scores ≥ 13 in a prior study 
[67]
Demographics Total sample (N = 44) Females (n = 27) Males (n = 17)
n M (SD)a Range n M (SD)a Range n M (SD)a Range
Age (years) 44 44.1 (13.5) 18–65 27 43.8 (12.8) 19–62 17 44.5 (14.9) 18–65
Hours worked per week (not parenting) 37 13.0 (16.8) 0–45 23 9.4 (15.5) 0–40 14 19.0 (17.7) 0–45
Fatigue severity (general fatigue)b 42 17.2 (3.0) 9–20 27 18.0 (2.4) 11–20 15 15.7 (3.4) 9–20
Duration of illness (years) 35 9.9 (6.9) .5–26 23 9.6 (7.1) .5–26 12 10.4 (6.6) 1–20
 Frequency short duration (≤ 3 years) 7 (15.9%) 5 (18.5) 2 (11.8%)
 Frequency long duration (> 3 years) 28 (63.6%) 18 (66.7%) 10 (58.8%)
 Unknown 9 (20.45%) 4 (14.81%) 5 (29.41%)
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ES estimates and confidence intervals for each outcome 
variable for the ITT sample.
The primary outcome for sleep, actigraphic sleep 
efficiency, revealed similar mean scores at baseline 
(M = 83.94, SD = 10.95) and post (M = 83.80, SD = 9.85) 
with a small effect estimate (µ2p = .03, p < .297) indicating 
no change in objective measurement of sleep efficiency. 
However, small improvements in perceived (Diary) sleep 
efficiency (µ2p =  .14, p =  .035) and sleep quality (PSQI: 
µ
2
p = .15, p = .027) were shown. There was also a reduc-
tion in awakenings during the night with approximately 
20% of the between-subjects variance accounted for 
by the intervention/time (actigraphy WASO: µ2p  =  .21, 
p = .004; diary WASO: µ2p = .20, p = .007).
Results for primary and secondary mood outcomes 
indicated minimal change in group mean scores across 
time. The primary mood outcome, POMS total score, 
revealed the lowest ES estimate (µ2p  =  .01, p  =  .649) 
compared with DASS subscales (depression: µ2p  =  .07, 
p =  .009; anxiety: µ2p =  .04, p =  .221; stress: µ2p =  .06, 
p = .151).
Five of the nine cognitive outcome variables revealed 
large ES estimates. The primary cognitive outcome, RVP 
A’, suggested an improvement in sustained attention from 
baseline (M = .91, SD = .42) to post (M = .94, SD = .04) 
with 53% of the between-subjects variance accounted for 
by the intervention/time (µ2p =  .53, p < .001). Secondary 
cognitive outcomes also indicated improvement across 
±
Fig. 2 Effect size estimates (µ2p = partial eta squared) and confidence intervals (C.I.) for clinical, microbial and lactate outcomes for the total sample 
across time. The cut‑off for large effects (µ2p > .14) is indicated by the dotted line. Asterisks (*) are used to identify primary outcomes. Change in 
mean scores for all clinical outcomes (sleep, mood, cognitive and other) were in the direction of improvement at post‑intervention. Change in 
mean scores on microbiota variables reduced at post‑intervention unless indicated (^). The d:l lactate variable ratio increased at post‑intervention 
(^). See Additional file 1: Table S1 for baseline and post descriptive statistics for each variable
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time in processing speed (µ2p =  .19, p =  .004), cognitive 
flexibility (µ2p =  .43, p  <  .001), story memory (μ2 =  .21, 
p = .002), and verbal fluency (µ2p = .14, p = .014).
The final clinical variable that suggested improvement 
was self-reported total symptoms (SSH) with group 
means reducing from baseline (M  =  28.42, SD  =  9.93) 
to post (M =  22.76, SD =  9.81) and approximately 29% 
of the between-subject variance attributed to the inter-
vention/time (µ2p  =  .29, p  =  .001). Notably, large sex 
effects were also observed for this variable with females 
(M = 31.14, SD = 8.16) reporting worse total symptoms 
compared to males (M = 23.00, SD = 11. 27) at baseline 
(µ2p = .18, p = .015).
Streptococcus count was the only microbial variable 
that showed a large effect for time (µ2p =  .21, p =  .003) 
with a reduction from baseline (M  =  8.69  ×  106, 
SD = 6.39) to post (M = 6.88 × 105, SD = 1.39 × 102). 
No interaction, time or sex effects were observed on the 
d-lactate outcome variable. Interestingly split-plot graphs 
of Streptococcus count (Fig.  3a),  RAaerobe (Fig.  3b), and 
 RAtotal (Fig. 3c) showed a spread of individual responses 
to the treatment with several participants increasing at 
post (count = 12/42,  RAaerobe = 17/42,  RAtotal = 13/42). 
In addition to this individual variability, accurate inter-
pretation of results from ITT analyses were limited by no 
placebo control and the possibility of practice effects on 
cognitive outcomes. To better understand associations 
between bacterial change and symptom expression the 
ancillary exploratory analyses were performed.
Ancillary exploratory analyses: correlations
Results of non-parametric correlations of variable 
change scores for the total sample, males and females 
are presented in Additional file 1: Tables S3–S5. Detailed 
ba
c
Fig. 3 Change in Streptococcus (a) count, (b) relative abundance within aerobic bacteria  (RAaerobe), and (c) relative abundance within total bacteria 
 (RAtotal) for individual cases before and after intervention.  indicates mean scores at baseline and post
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examination of the breadth of information provided 
by these ancillary analyses are beyond the scope of this 
paper. For the purposes of this article, only correlations 
with large effect sizes (rs > .5) are discussed to avoid over-
interpretation with smaller samples and the risk of Type 
1 error with multiple correlations. There were no large 
correlations between change in microbiota and clinical 
symptoms for the total sample (Additional file  1: Table 
S3). For females, results showed negative correlations 
(i.e., increased bacteria associated with clinical improve-
ment) between change in: Clostridium and cognitive flex-
ibility (rs = −  .58, p =  .002), Lactobacillus and planning 
(rs = −.50, p =  .010), and Enterococcus and story mem-
ory (rs = −.50, p = .015; Additional file 1: Table S4). The 
majority of large correlations were shown for males (see 
Additional file 1: Table S5). Table 3 provides a summary 
of large correlations between change in clinical symp-
toms and microbial and lactate change variables in males.
The correlations presented in Table  3 indicate some 
consistency across several clinical outcomes for the 
genera Bacteroides, Bifidobacterium, Clostridium and 
d:l Lactate variables. Negative correlations suggest that 
an increase in Bacteroides (as observed in 11/16 males) 
was associated with improvements in sleep (Actigra-
phy WASO, Sleep Quality—PSQI), mood (Mood Dis-
turbance—POMS Total; Stress—DASS), general fatigue 
(MFI-GF) and total symptoms (SSH). An association in 
the opposite direction was found for change on the cog-
nitive measure of planning (SWM-Strategy), which was 
reduced.
Negative correlations were shown between change in 
Bifidobacterium and sleep quality (PSQI), general fatigue 
Table 3 Summary of large spearman’s rho (rs) correlations (> .5) between clinical change and microbial or lactate change 
variables in males
N.B. Lower scores on clinical outcomes = improvement
a Variables with reversed correlations (i.e., multiplied by − 1) to allow for consistent interpretation
Microbial count and lactate change Clinical change rs p n Direction of change in bacteria associated 
with clinical improvement
Bacteroides Sleep quality—PSQI − .758 .011 10 Increase
General fatigue—MFI − .738 .004 13 Increase
Stress—DASS − .701 .011 12 Increase
Total symptoms—SSH − .600 .067 10 Increase
Mood disturbance—POMS total − .573 .066 11 Increase
Actigraphy wake after sleep onset − .529 .043 15 Increase
Planning—SWM—strategy .588 .017 16 Decrease
Bifidobacterium Sleep quality—PSQI − .681 .030 10 Increase
General fatigue—MFI − .602 .030 13 Increase
Anxiety—DASS − .567 .043 13 Increase
Visual learning—PAL—total errors − .529 .035 16 Increase
Clostridium Total symptoms—SSH .582 .078 10 Decrease
Verbal fluency—COWAT corrected  scorea .550 .027 16 Decrease
Story memory—LM  immediatea .522 .038 16 Decrease
Processing speed—RVP mean latency .507 .045 16 Decrease
Enterococcus General fatigue—MFI − .516 .071 13 Increase
Lactobacillus Actigraphy sleep onset latency .610 .016 15 Decrease
Attention—RVP A′a − .571 .021 16 Increase
Actigraphy sleep  efficiencya .512 .051 15 Decrease
Streptococcus Diary sleep onset latency − .656 .006 16 Increase
d:l Lactate ratio Actigraphy sleep onset latency .802 .001 14 Decrease
Total symptoms—SSH .567 .112 9 Decrease
General fatigue—MFI .532 .061 13 Decrease
Mood disturbance—POMS total .509 .110 11 Decrease
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(MFI), anxiety (DASS), and visual learning. Alternatively, 
positive correlations were revealed between change in 
Clostridium and total symptoms (SSH) and some cogni-
tive outcomes (verbal fluency, story memory, processing 
speed). Notably, change in Streptococcus correlated nega-
tively with perceived sleep onset (Diary SOL) indicating 
that reduced Streptococcus was associated with subjec-
tively longer time taken to fall asleep in males.
d:l Lactate
A small, negative correlation was observed between 
change in d:l lactate concentration ratios and change 
in Streptococcus count for the total sample (rs = −  .243, 
p =  .142). Correlations with clinical symptoms revealed 
that the change in d:l lactate concentration ratios was 
positively associated with change in sleep onset latency 
(actigraphy SOL), mood disturbance (POMS total) gen-
eral fatigue (MFI) and total symptoms (SSH) in males. 
This would suggest proportionally higher concentrations 
of d-lactate were associated with adverse symptoms in 
males. Proportionally higher concentrations of d-lac-
tate were seen in 9/15 males and 12/23 females at post 
intervention.
Harms
Six unexpected adverse events were reported from five 
participants. One participant (a) experienced severe diar-
rhoea, vomiting and cramping after taking the first anti-
biotic. This participant also experienced a respiratory 
allergic reaction to a non-protocol medication taken to 
attempt to relieve the gastrointestinal symptoms. Four 
other participants experienced an adverse event includ-
ing (b) blood in stool (bloating but no pain reported), (c) 
difficulty sleeping, (d) rash on torso, and (e) exacerba-
tion of Seborrheic dermatitis. Of these participants, the 
first (a) discontinued all treatment after the first antibi-
otic dose. The other participants (b) completed the treat-
ment protocol, (c) reduced antibiotics (consumed 20/24 
capsules), or reduced probiotics (d: consumed 11/28 cap-
sules, e: consumed 14/28 capsules), respectively. All par-
ticipants participated in post-intervention assessments.
Discussion
ITT analysis of effects across outcome variables showed 
reduction in Streptococcus count and improvement 
across multiple clinical outcomes with no clear sex dif-
ference in treatment effect. The clinical changes observed 
with this short intervention included large effects likely to 
reflect modest clinical improvement on some secondary 
sleep outcomes (wakefulness, efficiency, quality), primary 
and secondary cognitive outcomes (attention, processing 
speed, cognitive flexibility, story memory, verbal fluency) 
and total symptoms. Measures of mood, fatigue and 
d-lactate showed no (or low) treatment effects.
Improvement on some sleep and cognitive measures 
appear promising considering this short intervention 
(4-weeks) and the complexity of this chronic condition 
(average illness duration ~ 10 years). It is unclear whether 
clinical changes at post were a direct response to the 
treatment or better explained by placebo, practice effects 
(particularly cognitive outcomes) or symptom variabil-
ity of unknown origin. If placebo effects are the primary 
explanation for the results observed, we would have pre-
dicted consistent improvements across subjective vari-
ables (i.e., sleep, mood and fatigue variables) that were 
not shown. With these confounding factors in mind, 
improvement on objective sleep parameters may provide 
the most reliable indicator of change. Using these con-
servative parameters, reduced wakefulness after sleep 
onset (actigraphic WASO) may be the best indicator of 
clinical improvement.
Unexpectedly, individual variability of treatment 
response was highlighted by the proportion of par-
ticipants who increased in Streptococcus counts at post 
(count  =  28%,  RAaerobe  =  41%,  RAtotal  =  31%). This 
prompted exploration of relationships between change in 
microbial count and clinical symptoms. Ancillary results 
showed that shifts in microbiota were associated with 
more of the variance in clinical changes for males com-
pared with females. Smaller correlations for females may 
(i) suggest non-monotonic relationships, (ii) raise ques-
tions about the benefits of the intervention for this group, 
(iii) suggest that other unmeasured factors may contrib-
ute to the variance observed (i.e., changes in the microbi-
ome, hormonal, immune, other stressors) or (iv) indicate 
an alternate mode of action in females (i.e., not revealed 
by the methods carried out in this pilot study).
In males, change in Bacteroides, Bifidobacterium and 
Clostridium were associated with change across several 
symptoms. Intercorrelations between change in micro-
bial and clinical variables suggest that an increase in 
Bacteroides (count) was associated with improvement 
on some clinical measures of sleep, mood, fatigue and 
total symptoms. Similarly, increased Bifidobacterium 
was associated with improvement in sleep quality, gen-
eral fatigue, anxiety and visual learning. For Clostridium, 
a reduction was associated with more clinical improve-
ments (cognitive and total symptoms).
Previous findings suggest that it would be premature 
to conclude that these genera are only relevant for males 
with ME/CFS [26, 28, 68]. Armstrong et  al. [68] found 
reduced frequency of Bacteroides and increased fre-
quency of Clostridium in female ME/CFS patients com-
pared with controls. Decreased Bacteroides spp. in ME/
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CFS compared with controls and positive associations 
with serum amino acids [68] may be particularly relevant 
considering the role of amino acids for cellular energy 
[69]. Nagy-Szakal et al. [26] also found reduced propor-
tion of Bacteroides vulgatus but an increased abundance 
of ‘unclassified’ Bacteroides using sequencing techniques 
in ME/CFS patients without IBS symptoms. Prior evi-
dence combined with our results raise questions about 
the abundance, diversity and functional role of Bacte-
roides in ME/CFS. Therefore, a more reasonable explana-
tion for our ancillary results may be related to observed 
changes in our sample. For example, a larger proportion 
of males (11/16, 68.8%) increased in Bacteroides count at 
post compared with females (10/26, 38.5%). Rather than 
pointing to sex differences as a primary factor relevant 
for treatment response, our results could merely reflect 
individual variability or could imply increased complexity 
in females (i.e., the influence of other confounding fac-
tors such as hormonal shifts that may account for a larger 
percentage of the variance).
The growth in Bacteroides species at post for 11/16 
males may have occurred from cross-feeding through pro-
biotic supplementation. Metabolic by-products from one 
bacteria can become a food source (i.e., prebiotic) for other 
commensal bacteria [70]. Several Bifidobacteria species 
produce complex carbohydrates (exopolysaccharides) that 
can become substrates for other bacteria and subsequently 
promote their growth [70]. Some strains of Bifidobacte-
rium have been shown to increase species of Bacteroides 
using culture methods ex vivo [70, 71]. Whilst the strains 
analysed in prior studies are not directly comparable to 
the strains administered in this study (B. lactis, B. breve, 
B. longum), the possibility of similar metabolic processes 
should be considered. Our increasing understanding of 
cross-feeding and microbial communication (see review 
[33]) may be useful to identify probiotic or prebiotic treat-
ment alternatives to restore microbial homeostasis.
Relevance for d-lactate theory
The results of ITT outcome and ancillary analyses show-
ing no change in d:l lactate ratio at post and small neg-
ative correlations between change in d:l lactate and 
Streptococcus, raise doubts about d-lactate metabolism 
from Streptococcal species. Considering, 21/38 partici-
pants increased in d:l lactate ratio after the intervention, 
it appears that the reduction of Streptococcus did not 
decrease d-lactate concentrations as expected. Given the 
enteric microbiota consists of more than 1000 species of 
bacteria [33], the limitations with culture-based identifi-
cation methods, and the uncertainty around which spe-
cies are producing lactate, it is possible that a reduction in 
Streptococcus may have allowed another d-lactate produc-
ing organism to proliferate. Some ancillary results provide 
partial support for d-lactate theory in males with change 
scores indicating decrease of d:l lactate ratio associated 
with improvement on some clinical outcomes (sleep onset 
(actigraphy SOL), mood disturbance (POMS), general 
fatigue (MFI), and total symptoms (SSH)). Perhaps our 
results reflect the relative change in reduced l-lactate pro-
duction that would impact the ratio measured. Further 
research is needed to compare d-lactate concentrations 
(optimally in urine, faecal and serum samples) in ME/
CFS with healthy controls and investigate other possible 
d-lactate producing bacteria, to adequately evaluate the 
relevance of the d-lactate hypothesis for either sex.
Limitations
Our interpretation of d:l lactate is restricted by meth-
odological limitations requiring the use of a lactate 
ratio. The routine use of creatinine for normalising uri-
nary metabolites [72] may be inappropriate considering 
findings of higher creatinine concentrations in ME/CFS 
patients compared with controls [50]. Without an appro-
priate method for normalisation, absolute d-lactate con-
centrations and absolute l-lactate concentrations could 
not be statistically analysed because of the known wide 
variation in the concentration of spot urine samples in 
contrast to 24 h timed collections used to calculate daily 
excretion rates. Similarly, using genera rather than spe-
cies data for microbial outcomes has reduced specificity 
and restricts interpretation.
The open-label design without placebo-control and using 
repeated measures carries inherent limitations restrict-
ing interpretation and generalisability of findings. Whilst 
the placebo response appears to be lower in ME/CFS 
than other medical conditions (e.g., depression, migraine, 
gastro-intestinal conditions), the influence of participant 
expectation appears to be greater for interventions with 
physiological targets (i.e., infectious or immunological) 
compared with psychosocial interventions in ME/CFS 
[73]. Discrepancies between cognitive measures and other 
symptoms raise questions about the influence of practice 
effects inherent in repeated testing over a short interval. 
Whilst alternate forms and outcomes with reduced practice 
effects were prioritised (see Additional file  1: Additional 
Method), ideally, controlled comparison can be used in 
future research to ascertain the proportion of change that 
can be attributed to familiarity with cognitive tests.
Other confounding factors included the influence of 
diet, concurrent medication and fluctuating symptoma-
tology. Whilst we attempted to control for these factors 
by asking participants to remain stable on their diet and 
medication, the possibility of effects from other treat-
ments or dietary intake cannot be excluded. The nature 
of the condition is that it has symptomatology that can 
be exacerbated or diminished without clear attributional 
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cause. These fluctuations and other environmental 
(change in education or employment status, family stress-
ors) and/or physiological (e.g., stage of menstrual cycle, 
viral/bacterial exposure) factors could not be controlled.
Statistical limitations include reduced power with 
smaller male samples, consideration of multiplicity of 
analyses and restricted interpretation with correlations. 
Results from correlational data only provide information 
about monotonic relationships, cannot attribute causation 
and have limited capacity to infer direct treatment effects. 
Cautious interpretations have been made focusing on large 
effects to attempt to reduce bias and improve generalis-
ability. However, this conservative approach excludes small 
and moderate correlations that may also be relevant.
Other modes of action
Some lactate results that contradict d-lactate theory 
prompt consideration of whether Streptococcus spp. or the 
intervention could have other modes of action. Strepto-
coccal throat infections have been proposed as precipitat-
ing encephalitis and neurological symptoms in childhood 
(see [74–76]). Evidence of abnormal basal ganglia imaging 
and antibasal ganglia antibodies suggests that streptococ-
cal infections may trigger autoimmune responses in some 
individuals [76]. Within the context of ME/CFS, it seems 
reasonable to explore whether the overgrowth of com-
mensal enteric Streptococcus, as observed in 58/92 (59.2%) 
patients screened, may exert immunological or autoim-
mune effects that contribute to neurological symptoms. 
Future research could also evaluate a history of strepto-
cocci infections and monitor immune and inflammatory 
markers to establish whether similar mechanisms are at 
play in ME/CFS. Monitoring immune and inflammatory 
markers could be particularly beneficial considering anti-
biotic macrolides have immune-modulating properties 
that may be a mechanism responsible for improvement in 
this clinical sample (see [77]).
Another possible mechanism of the intervention is 
through the prokinetic qualities of erythromycin. Eryth-
romycin is a macrolide that inhibits protein synthesis 
in specific bacteria [78] and can increase gastric motil-
ity [79]. Low doses of erythromycin have been used for 
its prokinetic qualities in patients with delayed gastric 
emptying [80]. The stimulation of oesophageal, gastric 
and small intestinal contractions are likely to partially 
explain commonly reported gastrointestinal side effects 
(i.e., diarrhoea, nausea, vomiting) of oral erythromycin 
(see [81]). Therefore, the prokinetic effect of erythromy-
cin may be particularly beneficial for this sample when 
we consider that constipation is a common symptom 
for patients with comorbid IBS and/or small intestinal 
bacterial overgrowth (SIBO; [82]), and the prevalence 
of intestinal permeability in ME/CFS [20, 21]. Increased 
monitoring of gastrointestinal changes, SIBO and IBS 
symptoms would be useful in further studies.
Probiotics may also increase bowel transit [83] or have 
other modes of action. Possible mechanisms of probiotics 
include modulating inflammatory and immune responses 
through enhancing the epithelial barrier, adherence to 
the mucosal wall, direct (antimicrobial) or indirect (com-
petitive exclusion) effects on pathogenic microbiota, and 
vagal signalling (see [33, 84–86]). Metabolic by-products 
from specific bacterial strains may also effect clinical 
presentations through the production of neurotransmit-
ters (see [87]), short chain fatty acids through fermen-
tation (see [33]), and cross-feeding, as discussed above. 
Advances in metabolomics methods would be useful to 
monitor functional changes during probiotic supplemen-
tation in ME/CFS patients.
Conclusions
These results add to the accumulating evidence that 
microbiota–gut–brain interactions play a role in the 
clinical presentations of a subgroup of ME/CFS patients. 
This antimicrobial and probiotic treatment showed con-
current reduction in enteric Streptococcus counts and 
improvement in some neurological symptoms for the 
ITT sample. Precise mechanisms remain to be deter-
mined because results for d-lactate challenged the 
premise that Streptococcus species are the primary pro-
ducers of d-lactic acid. Other mechanisms including the 
immune-modulating properties of macrolides and probi-
otics could be explored.
Ancillary results infer that shifts in microbiota were associ-
ated with more of the variance in clinical changes for males 
compared with females. It is unclear whether the reduction 
in Streptococcus is particularly beneficial in some ME/CFS 
patients or whether other concurrent microbial shifts are 
equally or more valuable (i.e., reduced Bacteroides and/or 
increased Clostridium). Analysis of the microbiome through 
sequencing techniques should be examined to elucidate 
other microbial shifts not revealed through culture-based 
methods before pursuing a randomised placebo controlled 
trial. Whilst sex differences were not obvious through pri-
mary analyses, ancillary results reinforce the need to recruit 
sufficient samples to enable sex comparisons in clinical trials.
Individual differences in microbial and clinical changes 
observed across this intervention are unsurprising con-
sidering other prominent findings in gut microbiome 
and ME/CFS research. For example, ground-breaking 
research with a large healthy cohort has shown the 
microbiome as a primary predictor of varied glucose 
response to the same foods, supporting the need for per-
sonalised nutrition [88]. Within ME/CFS, duration of ill-
ness [89] and genetic variability [90–92] appear to be key 
factors that contribute to differences in immune markers, 
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pathophysiology and clinical presentation. Considering 
the bidirectional role of the gut microbiome in immune 
modulation (e.g., [93]), epigenetic regulation [94], and the 
influence of genetics on microbial composition [95], con-
tinued efforts to understand the function of the microbi-
ome in ME/CFS is warranted.
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